Nanostring Technologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- 703
- Market Cap
- -
- Website
- http://www.nanostring.com
Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- NanoString Technologies, Inc.
- Target Recruit Count
- 206
- Registration Number
- NCT02625935
- Locations
- 🇺🇸
New England Cancer Specialists, Scarborough, Maine, United States
🇺🇸North Shore Hematology Oncology Assoaciates, East Setauket, New York, United States
🇺🇸Florida Cancer Center, Fort Myers, Florida, United States
A Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2015-03-23
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- NanoString Technologies, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT02395575
- Locations
- 🇫🇷
Institut Curie, Paris, France
A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2015-09-16
- Lead Sponsor
- NanoString Technologies, Inc.
- Target Recruit Count
- 201
- Registration Number
- NCT01974856
- Locations
- 🇩🇪
Universitätsfrauenklinik Ulm, Ulm, Germany
🇩🇪Universitätsklinikum Kiel, Kiel, Germany
A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2015-03-19
- Lead Sponsor
- NanoString Technologies, Inc.
- Target Recruit Count
- 217
- Registration Number
- NCT01899079
- Locations
- 🇪🇸
Consorci Sanitari de Terrassa, Barcelona, Spain
🇪🇸Hospital Quirón Madrid, Madrid, Spain
🇪🇸Hospital U. Vall D'Hebron, Barcelona, Spain
© Copyright 2025. All Rights Reserved by MedPath